Lionco Pharmaceutical Group Co.,Ltd.

SHSE:603669 Stock Report

Market Cap: CN¥4.5b

Lionco Pharmaceutical GroupLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lionco Pharmaceutical GroupLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth19.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Nov 06
Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Oct 29
Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

May 10
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

Mar 12
There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lionco Pharmaceutical GroupLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SHSE:603669 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024277-102-92-81N/A
6/30/2024225-122-65-50N/A
3/31/2024200-145-55-42N/A
12/31/2023197-151-61-38N/A
9/30/2023189-223-95-48N/A
6/30/2023202-301-168-116N/A
3/31/2023237-239-165-110N/A
12/31/2022289-196-109-66N/A
9/30/2022338-824695N/A
6/30/20224633363108N/A
3/31/20225925176121N/A
12/31/20217406674129N/A
9/30/2021885877299N/A
6/30/20211,005153151207N/A
3/31/20211,01512999166N/A
12/31/20201,00116065127N/A
9/30/20201,1942037491N/A
6/30/20201,27216895103N/A
3/31/20201,530231242245N/A
12/31/20191,635202225236N/A
9/30/20191,69916787209N/A
6/30/20191,69022381233N/A
3/31/20191,70918621186N/A
12/31/20181,66918312186N/A
9/30/20181,610230131260N/A
6/30/20181,488171N/A207N/A
3/31/20181,209165N/A170N/A
12/31/20171,005161N/A189N/A
9/30/2017734149N/A160N/A
6/30/2017603140N/A143N/A
3/31/2017497156N/A149N/A
12/31/2016479154N/A182N/A
9/30/2016501151N/A114N/A
6/30/2016514152N/A118N/A
3/31/2016551148N/A138N/A
12/31/2015551150N/A99N/A
9/30/2015558155N/A157N/A
6/30/2015556150N/A174N/A
3/31/2015546142N/A151N/A
12/31/2014576150N/A181N/A
12/31/2013494115N/A161N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 603669's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 603669's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 603669's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 603669's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 603669's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 603669's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y